X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9927) 9927
Book Review (1514) 1514
Publication (819) 819
Conference Proceeding (39) 39
Book Chapter (21) 21
Magazine Article (15) 15
Dissertation (4) 4
Book / eBook (3) 3
Web Resource (3) 3
Paper (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9160) 9160
humans (8780) 8780
quinazolines - therapeutic use (5931) 5931
female (4804) 4804
oncology (4131) 4131
male (4110) 4110
middle aged (3358) 3358
aged (2918) 2918
lung neoplasms - drug therapy (2864) 2864
antineoplastic agents - therapeutic use (2776) 2776
quinazolines - pharmacology (2761) 2761
adult (2424) 2424
animals (2366) 2366
carcinoma, non-small-cell lung - drug therapy (2328) 2328
quinazolines - administration & dosage (2229) 2229
gefitinib (2190) 2190
erlotinib hydrochloride (2042) 2042
receptor, epidermal growth factor - antagonists & inhibitors (1997) 1997
cancer (1778) 1778
protein kinase inhibitors - therapeutic use (1725) 1725
treatment outcome (1699) 1699
antineoplastic combined chemotherapy protocols - therapeutic use (1647) 1647
quinazolines - adverse effects (1646) 1646
chemotherapy (1607) 1607
erlotinib (1496) 1496
receptor, epidermal growth factor - genetics (1391) 1391
cell line, tumor (1366) 1366
mutation (1344) 1344
mice (1284) 1284
lung neoplasms - pathology (1244) 1244
pharmacology & pharmacy (1233) 1233
lung neoplasms - genetics (1184) 1184
aged, 80 and over (1127) 1127
antineoplastic agents - pharmacology (1084) 1084
growth-factor receptor (1053) 1053
epidermal growth factor (1001) 1001
egfr (994) 994
tyrosine kinase inhibitor (971) 971
care and treatment (959) 959
receptor, epidermal growth factor - metabolism (918) 918
carcinoma, non-small-cell lung - genetics (900) 900
therapy (881) 881
lung cancer (874) 874
carcinoma, non-small-cell lung - pathology (863) 863
breast neoplasms - drug therapy (827) 827
adenocarcinoma - drug therapy (821) 821
cell lung-cancer (807) 807
research (792) 792
disease-free survival (781) 781
lung cancer, non-small cell (773) 773
expression (765) 765
protein kinase inhibitors - pharmacology (753) 753
analysis (727) 727
dose-response relationship, drug (717) 717
antineoplastic agents - adverse effects (692) 692
tumors (666) 666
clinical trials as topic (656) 656
cell proliferation - drug effects (639) 639
trial (639) 639
neoplasm staging (631) 631
prognosis (629) 629
breast cancer (627) 627
respiratory system (627) 627
survival (624) 624
hematology, oncology and palliative medicine (621) 621
medicine & public health (607) 607
tyrosine (605) 605
trastuzumab (604) 604
drug therapy (588) 588
antibodies, monoclonal, humanized (587) 587
apoptosis (586) 586
abridged index medicus (571) 571
drug resistance, neoplasm (562) 562
epidermal growth factor receptor (539) 539
signal transduction - drug effects (539) 539
non-small cell lung cancer (533) 533
lung neoplasms - mortality (526) 526
article (521) 521
mutations (520) 520
quinazolines - chemistry (518) 518
quinazolines - pharmacokinetics (509) 509
apoptosis - drug effects (499) 499
lapatinib (487) 487
neoplasms - drug therapy (486) 486
rats (485) 485
kinases (477) 477
adenocarcinoma (475) 475
antineoplastic combined chemotherapy protocols - adverse effects (473) 473
survival rate (473) 473
carcinoma, non-small-cell lung - mortality (470) 470
retrospective studies (469) 469
antibodies, monoclonal - therapeutic use (468) 468
metastasis (465) 465
health aspects (462) 462
deoxycytidine - analogs & derivatives (461) 461
breast neoplasms - pathology (460) 460
time factors (460) 460
tyrosine kinase inhibitors (457) 457
receptor, erbb-2 - metabolism (455) 455
resistance (449) 449
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9113) 9113
Japanese (221) 221
French (136) 136
Chinese (134) 134
German (118) 118
Spanish (58) 58
Italian (50) 50
Russian (43) 43
Hungarian (25) 25
Czech (19) 19
Polish (14) 14
Danish (9) 9
Norwegian (7) 7
Dutch (6) 6
Romanian (4) 4
Hebrew (3) 3
Croatian (2) 2
Finnish (2) 2
Portuguese (2) 2
Swedish (2) 2
Ukrainian (2) 2
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 10, pp. 947 - 957
This trial compared gefitinib, an inhibitor of the tyrosine kinase of epidermal growth factor (EGFR), with carboplatin plus paclitaxel as initial treatment of... 
CELL LUNG-CANCER | RECEPTOR GENE-MUTATIONS | MEDICINE, GENERAL & INTERNAL | THERAPY | FUNCTIONAL ASSESSMENT | PROSPECTIVE PHASE-II | 1ST-LINE GEFITINIB | EGFR MUTATIONS | TREATED PATIENTS | NEVER-SMOKERS | ERLOTINIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Carboplatin - adverse effects | Carboplatin - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Lung Neoplasms - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Paclitaxel - adverse effects | Adenocarcinoma - drug therapy | Paclitaxel - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Adenocarcinoma - mortality | Care and treatment | Dosage and administration | Nonsmokers | Gefitinib | Health aspects | Lung cancer | Chemotherapy | Pharmaceutical industry | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 16, pp. 1997 - 2003
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9840, pp. 475 - 483
Summary Background Addition of a sulphonylurea to metformin improves glycaemic control in type 2 diabetes, but is associated with hypoglycaemia and weight... 
Internal Medicine | ALL-CAUSE MORTALITY | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | ADD-ON | METAANALYSIS | GLUCOSE CONTROL | CARDIOVASCULAR-DISEASE | HYPOGLYCEMIA | RISK | MELLITUS | ASSOCIATION | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Purines - administration & dosage | Hypoglycemic Agents - administration & dosage | Treatment Failure | Adult | Female | Quinazolines - administration & dosage | Linagliptin | Purines - adverse effects | Purines - therapeutic use | Sulfonylurea Compounds - administration & dosage | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Sulfonylurea Compounds - therapeutic use | Treatment Outcome | Sulfonylurea Compounds - adverse effects | Diabetes Mellitus, Type 2 - blood | Quinazolines - therapeutic use | Quinazolines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Research Design | Type 2 diabetes | Complications and side effects | Dosage and administration | Metformin | Drug therapy | Hypoglycemic sulfonylureas | Sulfonylurea compounds | Glimepiride | Comparative analysis | Heart attacks | Diabetes | Pharmaceutical industry | Drug dosages | Index Medicus | Abridged Index Medicus | Drugs | Obesity | Body weight | Diabetes mellitus
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2015, Volume 26, Issue 1, pp. 113 - 119
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2006, Volume 355, Issue 26, pp. 2733 - 2743
Journal Article
Nature, ISSN 0028-0836, 03/2012, Volume 483, Issue 7387, pp. 100 - 104
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma(1). However, colon... 
PANITUMUMAB | TARGET | CETUXIMAB | MELANOMA | BRAF MUTATIONS | MULTIDISCIPLINARY SCIENCES | PAPILLARY THYROID-CARCINOMA | KRAS | METASTATIC COLORECTAL-CANCER | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - agonists | Apoptosis - drug effects | Colorectal Neoplasms - genetics | Humans | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | RNA Interference | Colorectal Neoplasms - drug therapy | HEK293 Cells | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Cetuximab | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Melanoma - metabolism | Colorectal Neoplasms - enzymology | Antibodies, Monoclonal - pharmacology | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Quinazolines - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Feedback, Physiological - drug effects | Indoles - therapeutic use | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Colorectal Neoplasms - pathology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Proteins | Library collections | Studies | Phosphorylation | Kinases | Tumors | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 135 - 144
Journal Article